Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

Katharine Bushby, Richard Finkel, David J. Birnkrant, Laura E. Case, Paula R. Clemens, Linda Cripe, Ajay Kaul, Kathi Kinnett, Craig M McDonald, Shree Pandya, James Poysky, Frederic Shapiro, Jean Tomezsko, Carolyn Constantin

Research output: Contribution to journalArticle

1032 Citations (Scopus)

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management.

Original languageEnglish (US)
Pages (from-to)77-93
Number of pages17
JournalThe Lancet Neurology
Volume9
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Duchenne Muscular Dystrophy
Pharmacology
Los Angeles
Live Birth
Gastroenterology
Centers for Disease Control and Prevention (U.S.)
Orthopedics
Guidelines

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., ... Constantin, C. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 9(1), 77-93. https://doi.org/10.1016/S1474-4422(09)70271-6

Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management. / Bushby, Katharine; Finkel, Richard; Birnkrant, David J.; Case, Laura E.; Clemens, Paula R.; Cripe, Linda; Kaul, Ajay; Kinnett, Kathi; McDonald, Craig M; Pandya, Shree; Poysky, James; Shapiro, Frederic; Tomezsko, Jean; Constantin, Carolyn.

In: The Lancet Neurology, Vol. 9, No. 1, 01.2010, p. 77-93.

Research output: Contribution to journalArticle

Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L, Kaul, A, Kinnett, K, McDonald, CM, Pandya, S, Poysky, J, Shapiro, F, Tomezsko, J & Constantin, C 2010, 'Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management', The Lancet Neurology, vol. 9, no. 1, pp. 77-93. https://doi.org/10.1016/S1474-4422(09)70271-6
Bushby, Katharine ; Finkel, Richard ; Birnkrant, David J. ; Case, Laura E. ; Clemens, Paula R. ; Cripe, Linda ; Kaul, Ajay ; Kinnett, Kathi ; McDonald, Craig M ; Pandya, Shree ; Poysky, James ; Shapiro, Frederic ; Tomezsko, Jean ; Constantin, Carolyn. / Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management. In: The Lancet Neurology. 2010 ; Vol. 9, No. 1. pp. 77-93.
@article{893754d59e24416f9b8b04adffcf4b09,
title = "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management",
abstract = "Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management.",
author = "Katharine Bushby and Richard Finkel and Birnkrant, {David J.} and Case, {Laura E.} and Clemens, {Paula R.} and Linda Cripe and Ajay Kaul and Kathi Kinnett and McDonald, {Craig M} and Shree Pandya and James Poysky and Frederic Shapiro and Jean Tomezsko and Carolyn Constantin",
year = "2010",
month = "1",
doi = "10.1016/S1474-4422(09)70271-6",
language = "English (US)",
volume = "9",
pages = "77--93",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of Duchenne muscular dystrophy, part 1

T2 - diagnosis, and pharmacological and psychosocial management

AU - Bushby, Katharine

AU - Finkel, Richard

AU - Birnkrant, David J.

AU - Case, Laura E.

AU - Clemens, Paula R.

AU - Cripe, Linda

AU - Kaul, Ajay

AU - Kinnett, Kathi

AU - McDonald, Craig M

AU - Pandya, Shree

AU - Poysky, James

AU - Shapiro, Frederic

AU - Tomezsko, Jean

AU - Constantin, Carolyn

PY - 2010/1

Y1 - 2010/1

N2 - Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management.

AB - Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management.

UR - http://www.scopus.com/inward/record.url?scp=72149108443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149108443&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(09)70271-6

DO - 10.1016/S1474-4422(09)70271-6

M3 - Article

C2 - 19945913

AN - SCOPUS:72149108443

VL - 9

SP - 77

EP - 93

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -